BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety

By WebmasterMarch 31, 2020November 1st, 2024No Comments

Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety

See more here

Previous PostOssianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.
Next PostRelmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development

Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostOssianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein.

Next PostRelmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development